Correction: 4-year results from the RAPID-PsA phase 3 randomised Placebo-Controlled trial of certolizumab pegol in psoriatic arthritis (RMD Open (2018) 4: (e000582). DOI: 10.1136/rmdopen-2017-000582)

Abstract

van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 2018;4:e000582. doi: 10.1136/rmdopen-2017-000582. Several changes were inadvertently missed during the production stage. These corrections are now incorporated into the current version.